“New evidence suggests that the purveyors of loyalty cards may even financially incentivize patients to push for brand- name drugs by ensuring that the patient’s co-pay is less for a brand name than a generic drug." https://t.co/GsdNm8sSDR https://t.co/196
Co-pay cards in Canada: Improving choice or institutionalizing bribes? https://t.co/iG0C3Kq3tB
RT @MA_Gagnon: My commentary in CMAJ on co-pay cards for brand-name drugs... or how we ended up institutionalizing corruption. Co-pay cards…
Great read how drug loyalty cards may: -encourage brand-name drug use -give #bigpharma access to patient info -increase prescriptions requiring Brand-name drugs -increase premiums & eventually rates -financially incentivize patients to ask for co
RT @MA_Gagnon: My commentary in CMAJ on co-pay cards for brand-name drugs... or how we ended up institutionalizing corruption. Co-pay cards…
My commentary in CMAJ on co-pay cards for brand-name drugs... or how we ended up institutionalizing corruption. Co-pay cards in Canada: Improving choice or institutionalizing bribes? https://t.co/HJgI5T9fyV
Co-pay cards likely waste resources, increase costs, and incentivize patients to push for brand-name drugs. New commentary by @MA_Gagnon: https://t.co/bqvd4TQQIS #CDNhealth https://t.co/vLbhimhA7t